Edition:
United Kingdom

Loxo Oncology Inc (LOXO.OQ)

LOXO.OQ on NASDAQ Stock Exchange Global Market

83.15USD
8 Dec 2017
Change (% chg)

$3.52 (+4.42%)
Prev Close
$79.63
Open
$80.19
Day's High
$84.96
Day's Low
$80.19
Volume
166,793
Avg. Vol
148,472
52-wk High
$95.78
52-wk Low
$25.30

Select another date:

Mon, Dec 4 2017

BRIEF-Loxo Oncology Announces Updated Larotrectinib Pediatric Clinical Trial Data Demonstrating Continued Durability Of Response In TRK Fusion Cancers

* LOXO ONCOLOGY ANNOUNCES UPDATED LAROTRECTINIB PEDIATRIC CLINICAL TRIAL DATA DEMONSTRATING CONTINUED DURABILITY OF RESPONSE IN TRK FUSION CANCERS

Loxo signs lucrative cancer drug deal with Bayer, but shares fall

Loxo Oncology on Tuesday signed a collaboration agreement for its promising cancer drugs with Germany's Bayer AG that could be worth up to $1.55 billion to the tiny U.S. company, but its shares fell 11 percent as the deal appeared to end near-term likelihood of a takeover.

UPDATE 4-Loxo signs lucrative cancer drug deal with Bayer, but shares fall

Nov 14 Loxo Oncology on Tuesday signed a collaboration agreement for its promising cancer drugs with Germany's Bayer AG that could be worth up to $1.55 billion to the tiny U.S. company, but its shares fell 11 percent as the deal appeared to end near-term likelihood of a takeover.

UPDATE 2-Loxo, Bayer to co-develop cancer drugs in up to $1.55 bln deal

Nov 14 Loxo Oncology will collaborate with Germany's Bayer to develop and commercialize two of its cancer therapies, the companies said, in a deal that could bring the U.S. drug developer up to $1.55 billion over the next few years.

BRIEF-Bayer, Loxo Oncology form partnership to develop, commercialise cancer drugs​

* Says it and loxo oncology to develop and commercialize two novel oncology therapies selectively targeting genetic drivers of cancer​

BRIEF-Loxo Oncology announces development and commercialization partnership with Bayer for cancer drugs

* Loxo Oncology announces global development and commercialization partnership with Bayer for larotrectinib and LOXO-195

Loxo Oncology to develop, commercialize cancer drugs with Bayer

Nov 14 U.S. drug developer Loxo Oncology Inc on Tuesday announced a deal with Bayer AG to develop and commercialize two of its cancer therapies and said it would receive $400 million upfront.

BRIEF-Loxo Oncology reports quarterly loss per share of ‍$2.45

* Loxo Oncology announces third quarter 2017 financial results

BRIEF-Loxo Oncology announces positive results from independent review committee assessment of larotrectinib dataset

* Loxo Oncology announces positive top-line results from independent review committee assessment of larotrectinib dataset

BRIEF-Loxo Oncology posts Q3 loss per share $1.14

* Loxo Oncology announces second quarter 2017 financial results

Select another date: